AB Science S.A.Company Review & Valuation

AB
Euronext Paris
Latest Price
7.17EUR
Market Capitalization
318.02mEUR

About AB Science S.A.

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company's lead compound is the Masitinib, a tyrosine kinase inhibitor that is in Phase III trials for the treatment of oShow more ncology, inflammatory, multiple sclerosis, Alzheimer's, and amyotrophic lateral sclerosis diseases. It also develops other compounds, such as KIT816 for the treatment of aggressive mastocytosis, seminoma, and acute myeloid leukemia; and Syk for treating rheumatoid arthritis/B-cell lymphoma. In addition, AB Science S.A. offers Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. The company markets its Masitinib under the Masivet brand in Europe; and Kinavet brand in the United States. It serves hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France. Show less

Industry
Drug Manufacturers - Major
HQ Location
Paris, France

Stock Price

Price data not available for AB Science S.A..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

back to top